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Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare genetic disorder caused by defective complement regulation
resulting in thrombotic microangiopathy (TMA). Patients can present as children or adults. The syndrome consists of
hemolytic anemia with schistocytosis, thrombocytopenia, significant renal damage, and/or other organ system
dysfunction(s). Patients with aHUS may succumb to the complications of the disease with the very first
manifestation; surviving patients often suffer from progressive organ dysfunction with significant morbidity and
mortality despite plasma infusion or plasma exchange. Eculizumab, a humanized monoclonal antibody to C5, was
approved for treatment of aHUS in 2011. This is an expensive but highly effective therapy changing the lives and
improving the outcome of patients with aHUS. Making timely and accurate diagnosis of aHUS can be life-saving if
eculizumab treatment is begun promptly. Finding a genetic mutation in a complement regulatory protein is
diagnostic with the appropriate clinical syndrome, but at least 30 % of patients do not have defined or reported
mutations. Thus the diagnosis rests on the clinical acumen of the physician. However, the clinical manifestations of
aHUS are shared by other etiologies of thrombotic microangiopathy. While laboratory finding of undetectable
ADAMTS13 activity defines TTP, distinguishing aHUS from the other causes of TMA remains an art. In addition, aHUS
can be unmasked by conditions with enhanced complement activation, such as systemic lupus erythematosus,
pregnancy, malignant hypertension, and hematopoietic stem cell transplantation. Thus if TMA occurs in the setting
of enhanced complement activation, one must consider aHUS as an underlying etiology, especially if treatment of
the condition does not resolve the TMA.
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Background
The clinical syndrome of organ dysfunction, microangiop-
athy hemolytic anemia and thrombocytopenia, most often
caused by various forms of thrombotic microangiopathy,
is a diagnostic enigma for the clinicians at the frontlines
evaluating the critically ill. Historically, with poor under-
standing of pathophysiologic mechanisms, and plasma ex-
change being the only accepted therapy, recognition of the
clinical syndrome was all that was needed to manage such
patients. The precise understanding of the diagnostic en-
tities within this syndrome in the last two decades, and
availability of a specific therapeutic option, are forcing cli-
nicians to retool their knowledge base in order to better
serve their patients. This article reviews the distinction be-
tween atypical hemolytic uremic syndrome and other
causes of thrombotic microangiopathy, especially
thrombotic thrombocytopenic purpura, and proposes a
diagnostic/management algorithm.
Review
What is thrombotic microangiopathy?
Thrombotic microangiopathy (TMA) is a pathologic
condition with abnormalities in the blood vessel walls of
arterioles and capillaries resulting in microvascular
thrombosis [1]. There are several disease states that can
lead to TMA (Table 1) [2, 3]. Clinically TMA is nearly
always accompanied by microangiopathic hemolytic
anemia (MAHA), a non-immune hemolytic anemia
resulting from intravascular red cell fragmentation with
schistocytosis and thrombocytopenia due to consump-
tion. The direct antiglobulin test (DAT) is negative, and
lactate dehydrogenase (LDH) is typically markedly ele-
vated; bilirubin is modestly increased, while haptoglobin
is undetectable. MAHA is most often caused by TMA,
but intravascular devices such as prosthetic heart valve
or left ventricular assist devices may also cause MAHA.
In addition, many systemic disorders can be associated
with MAHA with or without TMA (Table 2) [2, 3].
Rarely paroxysmal nocturnal hemoglobinuria and
heparin-induced thrombocytopenia can present with
MAHA and thrombocytopenia. It takes an astute clin-
ician with the proper laboratory acumen to decipher the
underlying cause of TMA/MAHA in a given patient.
Hemolytic uremic syndromes and TTP
Hemolytic uremic syndrome (HUS) affects children and
adults, and is characterized by MAHA, thrombocytopenia,
and significant renal dysfunction. In most cases HUS is
caused by Shiga-toxin bearing E coli; rarely pneumococcal
infection can also lead to HUS [4]. However, in a small
minority of patients, with so-called atypical hemolytic
uremic syndrome (aHUS), no infectious agent is found.
aHUS is a rare genetic disorder characterized by
complement-mediated TMA resulting from mutations af-
fecting the regulation of the alternative complement path-
way. Numerous loss of function mutations in factor H,
factor I, membrane cofactor protein, thrombomodulin, as
well as gain of function mutations in C3 and factor B, have
been discovered [5]. Patients present at all stages of life
despite the genetic nature of the disease, and it is poorly
understood what protects the patients from having disease
manifestations until later in life. Historically, HUS and
aHUS are discussed in the setting of thrombotic thrombo-
cytopenic purpura (TTP), as the pathophysiology under-
lying these disorders were not known, and the clinical
presentations are often indistinguishable. Since the reports
of absolute ADAMTS13 deficiency (von Willebrand
factor-cleaving metalloprotease) in TTP caused by auto-
immune antibody to ADAMTS13 in 1998 by Tsai [6] and
Furlan [7], TTP is now recognized as a distinct disorder
Table 1 Causes of TMA
Thrombotic thrombocytopenic purpura (TTP) Absence of ADAMTS13, the von Willebrand factor cleaving metalloprotease. Acquired due to
autoimmune antibody to ADAMTS13, or hereditary (Upshaw-Schulman syndrome).
Infectious hemolytic uremic syndrome (ST-HUS) Shiga toxins produced by Shigella dysenteriae and some serotypes of Escherichia coli (O157:H7
and O104:H4), cause direct damage to kidney epithelial and mesangial cells, and vascular
endothelial cells. Rarely pneumococcus or other infectious agents with neuraminidase can expose
the Thomsen-Friedenreich antigen on cell surfaces to result in hemolysis and direct endothelial injury.
Atypical or complement-mediated HUS Hereditary deficiency of complement regulatory proteins (factor H, factor H related proteins, factor
I, membrane cofactor protein, thrombomodulin) that normally regulate and restrict the activation
of the alternative complement pathway, or hereditary abnormalities (factor B, C3) that accelerate
the activation of the alternative complement pathway, leading to complement-mediated damage
to vascular endothelium and kidneys. Acquired deficiency of complement factor H or factor I can
be caused by autoimmune antibodies. Recessive mutations in diacylglycerol kinase epsilon (DGKE)
is thought to result in a prothrombotic state with TMA in infancy (distinct from DGKE nephropathy).
Plasminogen mutation was suggested to be the cause of aHUS in one case report.
Drug-induced TMA Immune-mediated caused by drug-dependent antibodies that damage platelets, neutrophils and
endothelial cells (quinine, gemcitabine, oxaliplatin and quetiapine). Dose-dependent toxicity-
mediated caused by direct endothelial damage (gemcitabine, mitomycin, cyclosporine, tacrolimus,
sirolimus, bevacizumab, oxymorphone).
Metabolism-mediated TMA Disorders of intracellular vitamin B12 metabolism due to mutations in the MMACHC gene. Associated
with elevated homocysteine and low methionine levels in plasma, with methylmalonic aciduria.
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with absence of detectable levels of ADAMTS13 ac-
tivity as the defining feature of TTP [8]. Thus infec-
tious HUS, atypical or complement-mediated HUS,
and TTP have distinct pathophysiological mechanisms,
and should no longer be regarded and treated as the
same disease.
Previously, there was no utility in making a diagnostic
distinction between HUS, aHUS and TTP as all patients
were treated with plasma exchange. Plasma exchange
remains the mainstay of therapy for TTP to remove
the autoimmune antibody and to replenish the absent
enzyme. Prognosis of TTP is excellent with early rec-
ognition of disease and prompt institution of plasma
exchange [9]. Proper antibiotic therapy and supportive
care is now considered the treatment of choice for in-
fectious HUS. Since September 2011, eculizumab, a
humanized monoclonal antibody against C5, was ap-
proved by the FDA for treatment of patients with
TMA secondary to aHUS. With the high response
rates of eculizumab and potential for renal recovery
in aHUS patients [10], separating the rare patient
with aHUS from infectious HUS and TTP is now a
clinical urgency.
Diagnostic approach to aHUS
When a critically ill patient with MAHA and
thrombocytopenia is encountered, the differential diagno-
ses listed in Tables 1 and 2 should be considered [2, 3].
Several entities should be easily ruled out on clinical
grounds, such as drugs, malignancy, pregnancy, hyperten-
sion and hematopoietic stem cell transplantation. Labora-
tory studies can identify rheumatologic disorders, B12
deficiency, antiphospholipid syndrome, and DIC. There-
fore, the main differential consideration is TTP versus in-
fectious HUS or atypical HUS. Infectious HUS can be
identified with diarrheal illness with positive testing for
the Shiga toxin; TTP now has a diagnostic test with
ADAMTS13 activity [11–15]. However, testing with rapid
turn-around time is not available at most institutions.
Clinical findings and laboratory data may be helpful. TTP
is not known to involve the lungs, and rarely results in liver
dysfunction. Renal disease is typically mild in TTP patients
(creatinine <1.7–2.3 mg/dL), while thrombocytopenia is
more severe (<30 × 109/L) compared to aHUS patients
[16, 17], but overlap is considerable (unpublished data); the
most recent patient diagnosed to have TTP at our institu-
tion had a creatinine of 5 mg/dL and platelet count of 47 ×
109/L. For atypical or complement-mediated HUS, while
finding a pathologic mutation in the regulatory proteins of
the alternative complement pathway is diagnostic, only a
few reference laboratories offer the genetic analysis, and
registry data show that at least 30 % of patients with aHUS
do not have currently known mutations. Genetic testing is
also expensive and time consuming; with the exception
of Machaon Diagnostics, the results are not available
for at least 3–4 weeks. Having a negative genetic ana-
lysis certainly does not rule out aHUS, and not all la-
boratories offer whole exome sequencing. Thus the
diagnosis of aHUS remains clinical. The recommended
approach is to initiate plasma exchange therapy while
waiting for diagnostic tests (such as ADAMTS13 activ-
ity) [18]. If ADAMT13 activity is below the level of
detection, TTP is diagnosed and plasma exchange is
continued until resolution of the MAHA and
thrombocytopenia. If ADAMTS13 is detectable, and
there is no diarrheal illness, then atypical HUS is the
most likely diagnosis; keep in mind that atypical HUS
especially in adults may present with a diarrheal illness
without Shiga-toxin, due to involvement of the gastro-
intestinal tract. Response to plasma exchange can be
helpful, with TTP patients responding in 3–5 days,
while the response in aHUS patients is at best partial
with improvement of hematologic parameters while
organ functions continue to worsen [18].
In summary, when a patient with MAHA,
thrombocytopenia and organ dysfunction, a detectable
level of ADAMTS13 activity and absence of Shiga-toxin
induced diarrheal illness should raise the clinical suspi-
cion for atypical or complement-mediated HUS. Empiric
plasma exchange should be initiated while waiting for
results of the ADAMTS13 activity and Shiga toxin test-
ing. Less than optimal response in 5 days to empiric
plasma exchange should heighten the suspicion that the
patient does not have TTP and treatment for aHUS
should be considered.
Conditions with augmented or enhanced complement
activation and aHUS
As mentioned in Table 2, there are several systemic con-
ditions or disorders that can present with MAHA,
thrombocytopenia, and organ dysfunction [2, 3]. These
are in fact conditions with enhanced complement
Table 2 Systemic disorders associated with TMA/MAHA




Systemic infections (viremia, fungemia)
Systemic malignancies (chemotherapy, tumor cell embolism)
Systemic rheumatologic disorders (systemic lupus, scleroderma,
catastrophic antiphospholipid syndrome)
Hematopoietic stem cell transplantation (myeloablative drugs, i
mmunosuppression, viremia/fungemia)
Intravenous radiologic contrast media or exposures to biomaterials
during vascular procedures
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activation that can potentially unmask patients with mu-
tations associated with aHUS. Registry data suggest that
aHUS presents with conditions with enhanced comple-
ment activation nearly 70 % of the time [19]. When
MAHA, thrombocytopenia, and organ dysfunction occur
in patients with such a condition, care must be taken to
monitor for prompt resolution of the hematologic ab-
normalities and organ dysfunction once the condition is
resolved. Persistence of the hematologic abnormalities
and/or organ dysfunction despite resolution of the con-
dition with enhanced complement activation should lead
to investigations for ADAMTS13 activity and/or Shiga
toxin depending on the clinical situation, and consider-
ation of empiric therapy with plasma exchange or initi-
ation of eculizumab. It should be noted that whether the
complement system is in fact enhanced or amplified is
difficult to determine. Blood complement levels and de-
tection of increased deposition of complement compo-
nents in microvasculature remain investigational.
Pregnancy
Fakhouri et al. conducted a retrospective analysis of 100
adult female patients with aHUS. 21 had pregnancy-
associated aHUS, and 79 % were post-partum. Mutations
associated with aHUS were detected in 18 of the 21 pa-
tients. The risk for pregnancy associated aHUS was
highest during a second pregnancy. Women with aHUS
and documented genetic defects were more likely to
have fetal loss and pre-eclampsia compared to those
with aHUS but no genetic abnormalities [20].
Similar to non-pregnancy-associated aHUS, differenti-
ating pregnancy-associated aHUS from other TMA is
difficult due to clinical resemblance with other disorders
including HELLP (hemolysis, elevated liver enzymes and
low platelets), AFLP (acute fatty liver of pregnancy), and
TTP. It is suggested that DIC picture and significant
liver dysfunction would point towards HELLP or AFLP,
and the absence of DIC and relatively normal liver en-
zymes are consistent with TTP or aHUS [21].
Pregnancy-associated TTP occurs in the late second or
third trimester, with a median time at 23 weeks. This is
thought to be related to the gradual rise of von Willeb-
rand factor concentration with advancing gestation while
ADAMTS13 activity decreases. In contrast, pregnancy-
associated aHUS occurs mostly in the post-partum
period, when effective control of the alternative comple-
ment pathway in the fluid phase is required [20].
The PROMISSE study is a multi-institutional observa-
tion study designed to identify predictors of pregnancy
outcome in patients with systemic lupus erythematosus
or positive antiphospholipid antibodies. Patients were
screened for mutations in membrane cofactor protein
(MCP), complement factor I (CFI), and complement fac-
tor H (CFH). Forty out of 250 patients (17 %) enrolled
had pre-eclampsia. Seven patients were found to have
mutations, and all 7 were amongst the 40 who had pre-
eclampsia. None of the 34 without pre-eclampsia
screened had a mutation documented. Thus in this study
17.5 % of patients with history of pre-eclampsia in the
setting of systemic lupus erythematosus or positive anti-
phospholipid antibodies had mutations associated with
aHUS. It is likely that mutations associated with aHUS
contributed to the development of pre-eclampsia in pa-
tients with lupus and/or antiphospholipid antibodies
(Fig. 1) [22].
To illustrate these points, the first patient at our institu-
tion treated with eculizumab for aHUS presented during
her third pregnancy at 20 weeks of gestation with marked
hypertension, and edema. She was admitted to the obstet-
ric service and treatment for presumed pre-eclampsia was
begun. However, despite lowering her blood pressure to
the near normal range and delivery of the nonviable fetus,
her creatinine increased to 4 mg/dL, while her
hemoglobin decreased to 6 g/dL and platelet count to
20 × 109/L. She had modest amount of schistocytes on the
blood smear, and ADAMTS13 activity was found to be
normal on two separate occasions. She did not have diar-
rhea. She was empirically treated with 7 days of plasma
exchange with minimal change in her clinical parameters.
At that point presumptive diagnosis of pregnancy-
associated aHUS was made, and she was initiated on ecu-
lizumab. By the second week of eculizuamb her
hematologic abnormalities and serum creatinine began to
normalize, with complete resolution of the disease mani-
festations by the fourth week. She has remained in remis-
sion as long as she is receiving eculizumab on schedule.
Malignant hypertension
While severe hypertension enhancing complement activity
is not established, both infectious and atypical HUS, are
often associated with significant hypertension. In contrast,
TTP is not associated with malignant hypertension. This
observed difference could be explained by a lower inci-
dence and lesser degree of renal disease in TTP compared
to HUS. Endothelial dysfunction is likely the common
mechanism linking malignant hypertension and TMA.
Endothelial dysfunction can result from either comple-
ment dysregulation, as seen in aHUS, or sheer stress in
malignant hypertension [23]. Thus it is possible that endo-
thelial injury from malignant hypertension can induce
MAHA in a patient with underlying complement dysregu-
lation (Fig. 1). An illustrative case is reported by Totina et
al. A 10-month old child presenting with malignant hyper-
tension and MAHA, but normal platelet count and nor-
mal renal function. Renal function and platelet count
deteriorated during the hospital course, and renal biopsy
demonstrated pathologic evidence of TMA. Molecular
The Author(s) Thrombosis Journal 2016, 14(Suppl 1):19 Page 154 of 163
analysis showed a complement factor H mutation of un-
known significance [24].
The distinction between malignant hypertension-
associated TMA and TMA causing malignant hyperten-
sion is an important one as TMA causing malignant
hypertension may well represent aHUS and respond to
eculizumab. Absence of retinal changes (cotton-wool
spots, flame hemorrhages, or retinal arteriolar narrow-
ing) is consistent with TMA causing malignant hyper-
tension, but not exclusively [23].
Systemic rheumatologic disorders
As mentioned above, complement dysregulation contrib-
utes to endothelial injury via the alternative pathway lead-
ing to TMA. In rheumatologic disorders such as lupus
erythematosus and antiphospholipid syndrome, auto-
immune antibodies form immune complexes, and activate
the complement system via the classical pathway [25]. Ac-
tive lupus is considered to be a risk factor for developing
TMA in a Korean study [26]. Thus patients with genetic
mutations associated with aHUS are particularly suscep-
tible to TMA when there is tissue damage from uncon-
trolled rheumatologic disorders (Fig. 1). Specifically, for
the integrity of the renal cells and glomerular basement
membane, complement regulation is of particular import-
ance [25]. Therefore, patients with rheumatologic disor-
ders such as lupus erythematosus and genetic mutations
associated with aHUS are particularly at risk for TMA.
Given the frequent occurrence of hemolytic anemia
and thrombocytopenia in lupus patients, recognizing
TMA in a lupus patient can be challenging. A Taiwanese
retrospective analysis of lupus patients with TMA
showed that while it is a rare occurrence at 1 % (consist-
ent with other reports), a high mortality rate of 52 % is
noted (prior to availability of eculizumab, despite plasma
exchange in the majority of patients) [27]. TTP again is
the main differential diagnosis when evaluating patients
with TMA in the setting of lupus, occurring in 1–4 % of
Fig. 1 Complement system in the pathogenesis of thrombotic microangiopathies. SLE: systemic lupus erythematosus; APS: antiphospholipid
syndrome; HTN: hypertension; HSCT: hematopoietic stem cell transplantation; CFH: complement factor H; CFI: complement factor I; MCP:
membrane cofactor protein; TM: thrombomodulin
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lupus patients with a high mortality [28]. Thus it is abso-
lutely important to obtain ADAMTS13 testing in a lupus
patient with TMA, and if ADAMTS13 activity is not ab-
sent, consider aHUS.
El-Husseini et al. reported a 24 year old female patient
with lupus and lupus nephritis who developed MAHA,
thrombocytopenia and worsening renal function despite
intensification of treatment for lupus nephritis. Repeat
kidney biopsy demonstrated both lupus nephritis and
TMA. While genetic testing was not performed, patient’s
clinical condition did not improve until eculizumab ther-
apy was instituted, and thus patient is presumed to have
developed aHUS in the setting of lupus and lupus neph-
ritis [29]. This case again illustrates the importance of rec-
ognizing possible aHUS as a cause of persistent TMA
when the underlying conditions with enhanced comple-
ment activation have been adequately treated. Investiga-
tions to identify risk features and determine the incidence
of aHUS amongst lupus patients with TMA are vital.
Stem cell transplant
Transplant-associated TMA is a frequently encountered
(~30 %) but poorly understood complication in recipi-
ents of hematopoietic stem cell transplantation (HSCT)
[30]. It is noted to be more frequent in older patients
and recipients of unrelated donor transplants, both of
which are risk factors for acute graft versus host disease.
It is more frequent in females, recipients of grafts with a
major or bidirectional ABO blood group mismatch. The
frequency of transplant-associated TMA correlated with
GvHD severity [31]. With the current knowledge that
endothelial cells are targets of acute GvHD (Fig. 1) [32],
patients with genetic defects affecting complement regu-
lation are thought to be more prone to develop
transplant-associated TMA. Jodele et al. studied the gen-
etic fingerprint of susceptibility for transplant-associated
TMA, and found that HSCT recipients with multiple
complement gene variants (≥3) are at high risk for se-
vere transplant-associated TMA [33]. Thus transplant-
associated TMA is likely a form of aHUS unmasked by
the endothelial dysfunction resulting from the condition-
ing regimen, GvHD, and possibly the use of calcineurin
inhibitors. In this particular type of TMA, absence of
ADAMTS13 activity is generally not observed, and treat-
ment with plasma exchange is rarely helpful [34]. Eculi-
zumab not surprisingly is found to be effective in high
risk transplant-associated TMA patients [30].
Conclusion
Atypical or complement-mediated HUS is a TMA
caused by mutations affecting the regulation of alterna-
tive complement pathway. Clinical presentation with
MAHA, thrombocytopenia, and significant organ dys-
function can mimic other TMA-causing entities. Absent
Fig. 2 Diagnostic algorithm for patients with thrombotic microangiopathies (TMA). MAHA: microangiopathic hemolytic anemia; TTP: thrombotic
thrombocytopenic purpura; HUS: hemolytic uremic syndrome
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ADAMTS13 activity rules in TTP, while diarrheal illness
with Shiga-toxin producing bacteria points toward infec-
tious HUS. When TMA occurs in the setting of condi-
tions with enhanced complement activity such as
pregnancy, rheumatic disorders, malignant hypertension,
and HSCT, persistence or worsening TMA despite treat-
ment of the associated conditions should raise the clin-
ical suspicion for aHUS (Fig. 2). If aHUS is reasonably
suspected, early intervention with anti-complement ther-
apy should be considered especially when extra-renal
complications are present; such patients are at increased
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